Navigation Links
Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
Date:3/13/2008

hat we are impacted by any of the risks identified above, we may not be able to continue in our business as planned.

For a complete discussion of the assumptions, risks and uncertainties related to our business, you are encouraged to review our filings with Canadian securities regulatory authorities, including our 2007 Annual Information Form filed on SEDAR at http://www.sedar.com. Historical filings relating to the Company prior to the completion of the Company's March 23, 2006 corporate reorganization may be reviewed on SEDAR at http://www.sedar.com under the SEDAR profile GVIC Communications Corp.

All forward-looking statements and information made herein are based on our current expectations as of the date hereof and we disclaim any intention or obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

Nventa Biopharmaceuticals Corp

Condensed Consolidated Statement of Operations

(Unaudited)

(Canadian dollars)(In thousands, except per share amounts)

Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006

Revenue:

Collaborative research

and development revenue $156 $156 $621 $621

Operating expenses:

Research and development 1,549 1,587 6,596 7,351

Selling, general and

administrative 922 714 4,529 3,565

Corporate restructuring 30 - 844 -

2,501 2,301 11,969 1
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
2. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
3. Nventa updates progress of cervical dysplasia trial with new HspE7
4. Nventas CEO to present at two upcoming investor conferences
5. Nventa announces publication of HspE7 data
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
8. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... A study presented at the 2014 ... of CSL Behring,s C1 Inhibitor (C1-INH) concentrate in ... sensitized patients. C1-INH is a human protein and ... The study shows that post-transplant treatment with ... of complement components 3 and 4, suggesting that ...
(Date:7/30/2014)... July 30, 2014 Sales Horizons, a ... of blended sales training programs for companies engaged in ... programs used by thousands of salespeople over 25 years ... training program can be customized to address the unique ... blended sales training program consists of two ...
(Date:7/30/2014)... July 30, 2014 Vycom announces the ... products, designed to meet Factory Mutual (FM) 4910 fire ... such as wet benches, process tools, fume hoods, furniture ... and damage to semiconductor wafers used in electronic chip ... flame-retardant PVC solution with excellent workability and superior aesthetics. ...
(Date:7/30/2014)... July 30, 2014   Epic Sciences, Inc. ... novel diagnostics to personalize and advance the treatment and ... Gregory T. Lucier as chairman of Epic,s board ... of Life Technologies (formerly Invitrogen). Mr. Lucier joins Epic,s ... its circulating rare cell analysis platform with special focus ...
Breaking Biology Technology:Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3
... Encorium Group, Inc. (Nasdaq: ENCO ... (CRO) that provides design, development, and management capabilities for ... world,s leading pharmaceutical companies, today announced the signing of ... both new business contracts and repeat business to be ...
... ETEX Corporation, a leading orthopaedic biomaterials company, ... 2.5cc sizes of Beta-bsm(TM) Injectable Paste and Gamma-bsm(TM) ... 10cc sizes. Both products are bone substitute materials ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080424/NETH117LOGO ...
... Hospira, Inc. (NYSE: HSP ), a ... today that Brian Meadows has been named corporate ... will be responsible for enterprise-wide supply chain operations ... supplier management; procurement; materials and production planning; transportation ...
Cached Biology Technology:Encorium Group Signs Approximately $2.0 Million of New Business Contracts 2Encorium Group Signs Approximately $2.0 Million of New Business Contracts 3ETEX Corporation Announces FDA Clearance of Small Size Beta-bsm(TM) Injectable Paste and Gamma-bsm(TM) Moldable Putty 2Hospira Names Brian Meadows Supply Chain Chief 2
(Date:7/30/2014)... (OUP) is pleased to announce its new relationship with ... OUP and CINP will partner to publish International ... fully open-access journal. , Alan Frazer, Editor-in-Chief of ... and expertise of OUP will further facilitate the goal ... the very leading journals within neuropsychopharmacology. The conversion of ...
(Date:7/30/2014)... $1 million from the Cornelia Cogswell Rossi Foundation to ... , The newly established Connie Cogswell Rossi ... a greater breadth and depth of knowledge of neurobehavioral ... of research to improve human health. , The new ... Laboratory and its external partners, supporting research to enhance ...
(Date:7/30/2014)... Soon, protection from HIV infection could be as simple ... sex. , University of Washington bioengineers have discovered ... that protects women from contracting HIV. Their method spins ... in contact with moisture, releasing higher doses of the ... gels or creams. , "This could offer women a ...
Breaking Biology News(10 mins):OUP to partner with the International College of Neuropsychopharmacology 2Rossi Foundation pledges $1M for JAX neurobehavioral research center 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3
... chocolate or the bitter taste of strychnine would seem to ... be hard-wired into the brain. Indeed, in studies with the ... in the January 19, 2006, issue of Neuron experiments demonstrating ... favor a model for taste encoding in the brain that ...
... announced today a critical step on the path of realizing ... described in the April 21 issue of Cell, the researchers ... ES cells that help explain the cells' rare ability to ... appear near the master genes that control embryonic development and ...
... equal. They are separated into categories A through C, ... easy to spread, kill effectively and call for special ... worrisome organisms is anthrax, which has already received its ... Fischetti's laboratory at Rockefeller University suggests that a newly ...
Cached Biology News:How taste response is hard-wired into the brain 2Novel molecular 'signature' marks DNA of embryonic stem cells 2Novel molecular 'signature' marks DNA of embryonic stem cells 3Newly discovered protein kills anthrax bacteria by exploding their cell walls 2
Rat monoclonal [20d5] to NKG2A + C+ E ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Mouse): CHO transfected cells expressing the B6 allele of NKG2A. Entrez Gen...
... has recently launched a custom synthesis ... (siRNA). Thermos siRNA molecules are: ... 2 DNA bases overhang at the ... Delivered fully deprotected and ready-to-use. ...
Rabbit polyclonal to STUB1 ( Abpromise for all tested applications). entrezGeneID: 10273 SwissProtID: Q9UNE7...
... orbital shaker stands both present ... ergonomic height, and help protect ... welded tubular steel, these heavy-duty ... the weight and minimize the ...
Biology Products: